

Trial of chemotherapy utilising carboplatin, vincristine, cyclophosphamide and etoposide for the treatment of central nervous system primitive neuroectodermal tumours of childhood

Submission date 01/07/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 23/01/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00003859

Secondary identifying numbers

CNS9102

Study information

Scientific Title

Trial of chemotherapy utilising carboplatin, vincristine, cyclophosphamide and etoposide for the treatment of central nervous system primitive neuroectodermal tumours of childhood

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Brain and nervous system cancer

Interventions

All patients receive surgery followed by either:

1. Schedule A: Radiotherapy alone
2. Schedule B: Initial chemotherapy (carboplatin, vincristine, cyclophosphamide and etoposide) followed by radiotherapy

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Carboplatin, vincristine, cyclophosphamide, etoposide

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1998

Completion date

28/01/2000

Eligibility

Key inclusion criteria

1. Aged 3 to 16 years
2. Survival period of at least 1 week following surgery
3. Post-operative Computed Tomography (CT) scan and myelogram
4. No concomitant haematological disorder
5. No previous history of malignant disease

Participant type(s)

Patient

Age group

Child

Lower age limit

3 Years

Upper age limit

16 Years

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1998

Date of final enrolment

28/01/2000

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123

Lincoln's Inn Fields

London

United Kingdom

WC2A 3PX

+44 (0)207 317 5186

kate.law@cancer.org.uk

Sponsor type

Charity

Website

<http://www.cancer.org.uk>

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	patient stratification results	15/08/2004		Yes	No
Results article	follow-up results	20/09/2007		Yes	No
Results article	results for supratentorial primitive neuro-ectodermal tumours (SPNET) subset	01/07/2009		Yes	No
Results article	radiotherapy duration results	15/03/2004	23/01/2019	Yes	No
Results article	results	15/04/2003	23/01/2019	Yes	No